Published December 7, 2022 | Version v1
Journal article Open

Prodrugs- A Regulatory Prospective

  • 1. Department of Pharmaceutical Chemistry, Advanced Institute of Pharmacy, Palwal, Haryana, India, 121105
  • 2. Department of Regulatory Affairs, Advanced Institute of Pharmacy, Palwal, Haryana, India, 121105

Description

ABSTRACT

Prodrugs are unique due to special features in contrast to drugs. The primary goal of prodrug design is to conceal harmful drug features, such as low solubility in water or lipid membranes, low target selectivity, chemical instability, undesirable taste, irritation or pain after local administration, presystemic metabolism and toxicity. The prodrug approach emphasizes on the improvements accomplished by developing the prodrug as compared to the free or parent drug. By determining market exclusivity, assessing viability and finding an optimum development pathway such as that offered by the 505(b)(2) process, developers may find that prodrugs present an ideal alternative to new drug development. There is no guidance on the acceptable development path for prodrugs. A clear understanding of what the classification means in terms of the studies required to support clinical development is needed.

Keywords: Prodrugs, regulatory perspective, patent, FDA Approval, regulatory pathways, challenges

Files

AJPTR126004.pdf

Files (397.1 kB)

Name Size Download all
md5:ce5c3bcffebe0cdfb5c2ada1ae7946cc
397.1 kB Preview Download